Slide 1: Interim report Q3 2011/12
Interim report Q3 2011/12 By CEO Lars Marcher and CFO Anders Arvai
Slide 2: Agenda
Agenda • Developments in Q3 2011/12 • Status of GPS Four • Outlook 2011/12
Slide 3: Highlights in Q3 2011/12
Highlights in Q3 2011/12 • Revenue growth of 9% • Continued improvements in earnings • Solid growth in the USA • Satisfactory growth in most of Europe – except for falling revenue in Spain • Positive development in Asia – continued strengthening of growth platform • Strong free cash flow • Focused g
Slide 4: Growth in revenue and profit
Growth in revenue and profit Revenue EBIT, DKKm Net profit for the period, 300 DKKm 50 50 250 40 40 200 30 30 150 100 20 20 50 10 10 0 0 0 • Revenue in Q3 2011/12 of • Gross margin ratio of • Net financials constitute DKK 263m, up 9%, or 5% 53.9% in Q3. expenses of DKK 3.1m when measured in local •
Slide 5: Development – markets
Development – markets USA, DKKm Europe, DKKm Rest of the world, DKKm 100 160 40 80 120 30 60 80 20 40 40 10 20 0 0 0 • Revenue growth of 9% • Growth in revenue of 2% • Growth in revenue in the in local currencies and and year to date 1% rest of the world of 6% in 21% in Danish kroner • Variation in
Slide 6: Development – business areas
Development – business areas Anesthesia, DKKm Patient Mon. & Diagnostics, DKKm Emergency Care, DKKm 120 140 50 120 100 40 100 80 80 30 60 60 20 40 40 20 20 10 0 0 0 • Fall in revenue of 1% in local • Revenue growth of 10% in • Revenue growth of 1% in currencies. Revenue year to local currencies in Q
Slide 7: Cash flow
Cash flow DKKm Q1-3 2010/11 Q1-3 2011/12 Cash flow from operating activities 54.3 86.6 Cash flow from investing activities, including (22.0) (63.9) acquisitions Free cash flow before acquisitions 32.3 52.7 Free cash flow after acquisitions 32.3 22.7 Cash flow from financing activities (26.4) 13.6 •
Slide 8: GPS Four – Status of Ambu's business strategy
GPS Four Status of Ambu’s business strategy
Slide 9: GPS Four – overview
GPS Four — overview PLATFORM DEVELOPMENT 2009-2010 Establishment of sales regions Establishment of global innovation organisation Implementation of global IT systems Moving of remaining production in Denmark to Asia initiated Expansion of factory in China Ambu* Ideas that work for life © COST OPTIMI
Slide 10: Update on GPS Four strategy
Update on GPS Four strategy • Product development: Work is going into developing two important new visualisation products – which are progressing according to plan – as well as updates of existing products. • Internal sales team in the USA, currently comprising 12 people, has increased sales via tel
Slide 11: Outlook 2011/12
Outlook 2011/12
Slide 12: Outlook 2011/12
Outlook 2011/12 2011/12 Comments Revenue In the range of DKK 1,040- Increased revenue in emerging markets and 1,050m (including acquired electrode successful introduction of new products Growth business) Approx. 4% Measured in local currencies Approx. 7% Measured in DKK Approx. 3% Organic growth as
Slide 13: General market conditions
General market conditions Favourable prospects for medicotechnical industry Ageing population • Favourable demographic developments – ageing and increase population, longer lifespans and increase in obesity and in chronic Declining diseases chronic illnesses power of Increase in critical care • Tota
Slide 14: Effective exploitation of possibilities
Effective exploitation of possibilities • Products targeted at treatments at clinics and in home care, intensive care and obese patients • Focus on single-use electronics, visualisation and wireless sensors • Continuous focus on emerging markets and optimisation in Europe and the USA • Larger volume
Slide 15: Questions
Ambu* Ideas that work for life Questions
Slide 16: Read more at www.ambu.com – contact details
READ MORE AT WWW.AMBU.COM For further information, please contact: CEO Lars Marcher, lm@ambu.com or +45 5136 2490 CFO Anders Arvai, aa@ambu.com or +45 7225 2000